Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMI-137 for MFGS in Papillary Thyroid Cancer
NCT03470259Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emi-137 in papillary thyroid cancer (PTC) (4 arms), sponsored by University Medical Center Groningen. Primary endpoint: Feasibility of Molecular Fluorescence Guided Surgery using EMI-137 at 1.5 years. Started Jun 2018; status: completed.
02
Drugs
emi-137
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NCT03470259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470259.